益生菌干预调节便秘儿童的肠道微生态研究

注册号:

Registration number:

ChiCTR1900024630 

最近更新日期:

Date of Last Refreshed on:

2019-07-23 10:58:54 

注册时间:

Date of Registration:

2019-07-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

益生菌干预调节便秘儿童的肠道微生态研究

Public title:

Intestinal microecology study for probiotics intervention in children with constipation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

益生菌干预调节便秘儿童的肠道微生态研究

Scientific title:

Intestinal microecology study for probiotics intervention in children with constipation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘建 

研究负责人:

刘建 

Applicant:

Liu Jian 

Study leader:

Liu Jian 

申请注册联系人电话:

Applicant telephone:

+86 0531-88755508

研究负责人电话:

Study leader's
telephone:

+86 0531-88755508

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

tankelj@126.com

研究负责人电子邮件:

Study leader's E-mail:

tankelj@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市高新区颖秀路2755号

研究负责人通讯地址:

山东省济南市高新区颖秀路2755号

Applicant address:

2755 Yingxiu Road, High-Tech Zone, Ji'nan, Shandong, China

Study leader's address:

2755 Yingxiu Road, High-Tech Zone, Ji'nan, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东探克生物科技股份有限公司

Applicant's institution:

Shandong tanke Biotechnology Co., Ltd.

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ETYY-2019006

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

济南市儿童医院医学伦理委员会

Name of the ethic committee:

Ji'nan Children's Hospital Medical Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

张柳

Contact Name of the ethic committee:

Zhang Liu

伦理委员会联系地址:

山东省济南市经十路23976号

Contact Address of the ethic committee:

23976 Jingshi Road, Ji'nan, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东大学齐鲁儿童医院

Primary sponsor:

Qilu Children's Hospital of Shandong University

研究实施负责(组长)单位地址:

山东省济南市经十路23976号

Primary sponsor's address:

23976 Jingshi Road, Ji'nan, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东省

市(区县):

济南市

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东大学齐鲁儿童医院

具体地址:

经十路23976号

Institution
hospital:

Qilu Children's Hospital of Shandong University

Address:

23976 Jingshi Road

经费或物资来源:

山东大学齐鲁儿童医院

Source(s) of funding:

Qilu Children's Hospital of Shandong University

研究疾病:

便秘  

Target disease:

constipation

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1、研究发现儿童便秘治疗过程中对肠道微生态的影响机制及有益菌株的破坏程度,发现儿童便秘疾病的新标记物。 2、研究发现益生菌干预调节便秘儿童肠道微生态的有利机制,对比患儿肠道微生态的恢复程度,发现不同的有益菌株,为之后儿童便秘预防和精准化治疗提供个性化有益菌株选择。  

Objectives of Study:

1. The study found that the mechanism of intestinal microecology during the treatment of constipation in children and the degree of damage of beneficial strains, found new markers of constipation in children. 2. The study found that probiotics intervention to regulate the intestinal micro-ecological mechanism of constipation children, compare the degree of recovery of intestinal micro-ecology in children, found different beneficial strains, provide personalized beneficial strain selection for post-child constipation prevention and precision treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1 既往或入组时已患有严重的心血管系统、消化系统、神经精神系统、泌尿系统等器官功能障碍及全身性疾病;
2 有腹部手术史;
3 入组时合并有全身性感染;
4 在一个月内有全身使用抗生素、抗真菌药、激素等影响微生态状况的药物,在一个月内有口腔局部用药:激素、抗生素等;
5 服用钙离子拮抗剂、抑酸剂、镇静剂、抗焦虑药及各种减肥药者。

Exclusion criteria:

1 Have had serious cardiovascular system, digestive system, neuropsychiatric system, urinary system and other organ dysfunction and systemic diseases in the past or when enrolled;
2 History of abdominal surgery.
3 Combined with systemic infection at the time of enrollment;
4 Within one month, there are antibiotics, antifungal drugs, hormones and other drugs that affect micro-ecological conditions, and there are oral local medications within one month: hormones, antibiotics, etc.
5 Taking calcium ion antagonists, acid suppressants, sedatives, anti-anxiety drugs and various diet pills.

研究实施时间:

Study execute time:

From 2019-07-22 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-07-22 00:00:00 To 2020-12-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

150

Group:

Group 1

Sample size:

干预措施:

益生菌干预

干预措施代码:

Intervention:

Probiotic intervention

Intervention code:

组别:

对照组

样本量:

150

Group:

Group 1

Sample size:

干预措施:

正常治疗未服益生菌

干预措施代码:

Intervention:

Normal treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东大学齐鲁儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Qilu Children's Hospital of Shandong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

16S rDNA

指标类型:

主要指标

Outcome:

16S rDNA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

stool

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 1 years
最大 Max age 14 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用分层随机法

Randomization Procedure (please state who generates the random number sequence and by what method):

Hierarchical random method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内以邮件形式公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The mail has been published within 6 months after the completion of the trial.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2019-07-19 15:01:47